Lentiviral Transfer of γ-Globin with Fusion Gene NUP98-HOXA10HD Expands Hematopoietic Stem Cells and Ameliorates Murine β-Thalassemia

被引:5
|
作者
Zhao, Hui Fen [1 ]
Abraham, Allistair [1 ]
Kim, Yoon-Sang [1 ]
Wang, Yong-Dong [2 ]
Pestina, Tamara [1 ]
Zhan, Jun [1 ]
Humphries, Keith [3 ]
Nienhuis, Arthur W. [1 ]
Persons, Derek A. [1 ]
机构
[1] St Jude Childrens Res Hosp, Div Expt Hematol, 262 Danny Thomas Pl,MS 341, Memphis, TN 38105 USA
[2] St Jude Childrens Res Hosp, Dept Computat Biol, Memphis, TN 38105 USA
[3] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada
关键词
CD34(+) CELLS; IN-VITRO; REPOPULATING CELLS; THERAPY; VECTOR; EXPANSION; DISEASE; VIVO; DIFFERENTIATION; EXPRESSION;
D O I
10.1016/j.ymthe.2017.01.019
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recently, an engineered Homeobox-nucleoporin fusion gene, NUP98-HOXA10HD or NA10HD, was reported to expand and maintain murine hematopoietic stem cells (HSCs). We postulated that NA10HD would increase the number of human gamma-globin-expressing cells to therapeutic levels. We developed a double gene lentiviral vector encoding both human gamma-globin and NA10HD, which was used to transduce human peripheral blood CD34(+) cells and increased engraftment 2- to 2.5-fold at 15 weeks post -transplantation in immunodeficient mice. In beta-thalassemic mice transplanted with beta-thalassemic HSCs transduced with the gamma-globin/NA10HD vector, the number of fetal hemoglobin (HbF)-expressing cells was significantly increased after 3 months, leading to resolution of the anemia. Furthermore, the increases in HbF were maintained at 6 months and persisted after secondary transplantation. In addition, NA10HD enrichment of transduced HSCs led to HbF increases without affecting homeostasis of the white blood cell lineages. Our results suggest that NA10HD increases the number of gamma-globin-transduced HSCs that engraft, leading to an elevated number of fetal hemoglobin-containing red cells. These effects of NA10HD provide an improved platform for testing of the therapeutic efficacy of novel globin vectors and provide further impetus to develop safe and effective methods for selective expansion of genetically modified cells.
引用
收藏
页码:593 / 605
页数:13
相关论文
共 37 条
  • [31] High-level erythroid lineage-directed gene expression using globin gene regulatory elements after lentiviral vector-mediated gene transfer into primitive human and murine hematopoietic cells
    Hanawa, H
    Persons, DA
    Nienhuis, AW
    HUMAN GENE THERAPY, 2002, 13 (17) : 2007 - 2016
  • [32] Reduction of HLH-like Manifestations in Murine Model of Munc13-4 Deficiency Following Lentiviral Gene Transfer into Hematopoietic Stem and Progenitor Cells
    Soheili, Tayebeh-Shabi
    Sepulveda, Fernando
    Durand, Amandine
    Riviere, Julie
    Martin, Samia
    de Saint Basile, Genevieve
    Cavazzana, Marina
    Andre-Schmutz, Isabelle
    MOLECULAR THERAPY, 2016, 24 : S300 - S300
  • [33] Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin Vector
    Cavazzana, Marina
    Ribeil, Jean-Antoine
    Payen, Emmanuel
    Suarez, Felipe
    Beuzard, Yves
    Touzot, Fabien
    Cavallesco, Resy
    Lefrere, Francois
    Chretien, Stany
    Bourget, Philippe
    Monpoux, Fabrice
    Pondarre, Corinne
    Neven, Benedicte
    Schmidt, Manfred
    von Kalle, Christof
    Kuypers, Frans A.
    Sandler, Laura
    Soni, Sandeep
    Hermine, Olivier
    Blanche, Stephane
    De Montalembert, Mariane
    Hacien-Bey-Abina, Salima
    Leboulch, Philippe
    BLOOD, 2015, 126 (23)
  • [34] Early Results of a Phase I/II Study of Gene Therapy for β-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral βAT87Q-Globin Vector
    Soni, Sandeep
    Thompson, Alexis A.
    Walters, Mark
    Leboulch, Philippe
    Cavazzana, Marina
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S28 - S29
  • [35] Recombinant scAAV2 Vector-Mediated Ex Vivo Transduction of Primary Human Hematopoietic Stem Cells from a β-Thalassemia Patient and Human β- Globin Gene Expression in a Murine Xenograft Model in Vivo
    Song, Liu-Jiang
    Zhang, Xin-Hua
    Zhu, Jun
    Wu, Jue-Lian
    Yin, Xiao-Ling
    Tan, Meng-Qun
    BLOOD, 2014, 124 (21)
  • [36] Initial Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for β-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral βA-T87Q Globin Vector (LentiGlobin BB305 Drug Product)
    Thompson, Alexis A.
    Rasko, John E.
    Hongeng, Suradej
    Kwiatkowski, Janet L.
    Schiller, Gary
    von Kalle, Christof
    Cavazzana, Marina
    Leboulch, Philippe
    Petrusich, Alexandria
    Soni, Sandeep
    Walters, Mark C.
    BLOOD, 2014, 124 (21)
  • [37] Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product)
    Walters, Mark C.
    Rasko, John
    Hongeng, Suradej
    Kwiatkowski, Janet
    Schiller, Gary J.
    Kletzel, Morris
    Ho, P. Joy
    Vichinsky, Elliott
    von Kalle, Christof
    Cavazzana, Marina
    Leboulch, Philippe
    Petrusich, Alexandria
    Soni, Sandeep
    Thompson, Alexis A.
    BLOOD, 2015, 126 (23)